[1]. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:10.3322/caac.21590.
[2]. Bunn PA Jr, Dimou A. Systemic Therapy for Elderly Patients with Advanced Non-Small-Cell Lung Cancers. J Clin Oncol. 2018;36(25):2571-2574. doi:10.1200/JCO.2018.79.2457.
[3]. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8-10. doi:10.1200/JCO.1995.13.1.8.
[4]. Dingemans AC, Hendriks LEL, Berghmans T, et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol. 2019;14(12):2109-2119. doi: 10.1016/j.jtho.2019.07.025.
[5]. Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672-1682. doi:10.1016/S1470-2045(16)30532-0.
[6]. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018;4(1):e173501. doi:10.1001/jamaoncol.2017.3501.
[7]. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051-2058. doi:10.1016/S0140-6736(18)32487-5.
[8]. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82(2):197-203. doi: 10.1016/j.lungcan.2013.07.026.
[9]. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009.
[11]. Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30(13):1447-1455. doi:10.1200/JCO.2011.39.5269.
[12]. Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30(13):1447-1455. doi:10.1200/JCO.2011.39.5269.
[13]. Li H, Li J, Wang X, et al. Promising Clinical Outcome with Long Term Follow-Up After Body Gamma Knife Stereotactic Radiosurgery for Patients with Early Stage Non-Small Cell Lung Cancer. Front Oncol. 2018; 8:618. Published 2018 Dec 21. doi:10.3389/fonc.2018.00618.
[14]. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(1):117-125. doi: 10.1016/j.ijrobp.2006.04.013.
[15]. De Rose F, Cozzi L, Navarria P, et al. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. Clin Oncol (R Coll Radiol). 2016;28(1):13-20. doi: 10.1016/j.clon.2015.08.011.
[16]. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878-886. doi: 10.1016/j.ijrobp.2011.08.036.
[17]. Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cárdenes HR. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol. 2016;6(2):86-95. doi: 10.1016/j.prro.2015.10.011.
[18]. Correa RJ, Salama JK, Milano MT, Palma DA. Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management. Cancer J. 2016;22(4):247-256. doi:10.1097/PPO.0000000000000202.
[19]. Heitmann J, Guckenberger M. Perspectives on oligometastasis: challenges and opportunities. J Thorac Dis. 2018;10(1):113-117. doi:10.21037/jtd.2017.12.77.
[20]. Xu Q, Zhou F, Liu H, et al. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. J Thorac Oncol. 2018;13(9):1383-1392. doi: 10.1016/j.jtho.2018.05.019.
[21]. DeGregorio M, Soe L, Wolf M. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis. 2014;6(6):571-573. doi: 10.3978/j.issn.2072-1439.2014.05.15.
[22]. Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51(16):2321-2329. doi: 10.1016/j.ejca.2015.07.035.
[23]. Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65-85. doi:10.3322/caac.21358.